NCT01828112 2025-02-07LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibNovartisPhase 3 Completed231 enrolled 33 charts
NCT01828099 2025-01-16LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerNovartisPhase 3 Completed376 enrolled 34 charts 1 FDA
NCT02299505 2022-02-09Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)NovartisPhase 1 Completed306 enrolled
NCT02450903 2021-03-30LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.NovartisPhase 2 Completed20 enrolled 12 charts
NCT01685138 2019-03-26LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerNovartisPhase 2 Completed124 enrolled 18 charts